Screener
Rhythm Pharmaceuticals, Inc. RYTM Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Lease liability | 676 | 650 |
| Deferred revenue | 48 | 194 |
| Deferred royalty obligation, current | 10,130 | 7,296 |
| Total current liabilities | 103,198 | 105,942 |
| Long-term liabilities: | ||
| Deferred royalty obligation | 98,339 | 100,886 |
| Lease liability, non-current | 3,163 | 3,342 |
| Total liabilities | 204,700 | 210,170 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s total current liabilities?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported total current liabilities of $103.2M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s total current liabilities decreased by 7.7% year-over-year, from $111.82M to $103.2M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s total current liabilities has grown at a 42.6% compound annual growth rate (CAGR), from $17.99M to $105.94M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude